1 results match your criteria: "Departments of Neuroscience Yale University School of Medicine New Haven Connecticut USA.[Affiliation]"
Article Synopsis
- Current methods for treating sporadic Alzheimer's mainly target amyloid beta and tau but overlook the critical issue of calcium dysregulation, which is significant in the disease's earlier stages.
- The study explores the effects of a GCPII inhibitor, 2-MPPA, on aged macaques to see if it can enhance calcium signaling and reduce tau hyperphosphorylation.
- Results indicated that 2-MPPA treatment led to lower levels of tau pathology and correlated with cognitive improvements, suggesting that targeting GCPII may be a promising strategy for addressing Alzheimer's-related inflammation.*